HHS moved to expand access to certain experimental peptides by issuing a policy that allows licensed pharmacies and physicians to temporarily compound six peptides without federal enforcement risk. The change reportedly follows pushback and concerns raised by FDA career scientists, who questioned the evidence base for safety and effectiveness. The policy is the latest example of regulators wrestling with how to handle low-evidence, high-demand compounds—especially when patient access pressure runs ahead of clinical data generation. For biotech and medtech stakeholders, it also underscores how quickly policy can shift the risk calculus for off-label and non-approved therapeutics. Companies with peptide programs or adjacent business models may need to reassess their compliance posture, manufacturing documentation, and labeling strategy as the policy could affect demand signals and competitive dynamics.